KRN-633

CAS No. 286370-15-8

KRN-633( KRN633 | KRN-633 | KRN 633 )

Catalog No. M18365 CAS No. 286370-15-8

KRN-633 is an effective VEGFR inhibitor. The IC50s of KRN-633 for VEGFR1, VEGFR2, and VEGFR3 is 170, 160 and 125 nM, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 53 In Stock
5MG 86 In Stock
10MG 138 In Stock
25MG 228 In Stock
50MG 332 In Stock
100MG 494 In Stock
500MG 1071 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    KRN-633
  • Note
    Research use only, not for human use.
  • Brief Description
    KRN-633 is an effective VEGFR inhibitor. The IC50s of KRN-633 for VEGFR1, VEGFR2, and VEGFR3 is 170, 160 and 125 nM, respectively.
  • Description
    KRN633 is a potent and selective VEGFR inhibitor. which inhibits tyrosine phosphorylation of VEGFR-2 (IC50 = 1.16 nmol/L) in human umbilical vein endothelial cells. Selectivity profiling with recombinant tyrosine kinases showed that KRN633 is highly selective for VEGFR-1, -2, and -3. KRN633 inhibits tumor growth in several in vivo tumor xenograft models with diverse tissue origins, including lung, colon, and prostate, in athymic mice and rats. KRN633 also causes the regression of some well-established tumors and those that had regrown after the cessation of treatment. KRN633 was well tolerated and had no significant effects on body weight or the general health of the animals. KRN633 might be useful in the treatment of solid tumors and other diseases that depend on pathologic angiogenesis. (In Vitro):KRN-633 inhibits tyrosine phosphorylation of VEGFR-1, VEGFR2, c-Kit, and PDGFR-β (IC50=11.7, 1.16, 8.01, 130 nM) in human umbilical vein endothelial cells. KRN-633 also inhibits the VEGF-driven proliferation of HUVECs (IC50=14.9 nM). KRN-633 suppresses capillary tube formation of endothelial cells.(In Vivo):KRN-633 inhibits tumor growth in several tumor xenograft models with diverse tissue origins, including lung, colon, and prostate, in athymic mice and rats. KRN-633 also causes the regression of some well-established tumors and those that have regrown after the cessation of treatment. KRN-633 is well tolerated and has no significant effects on body weight or the general health of the animals. Histologic analysis of tumor xenografts treated with KRN-633 reveals a reduction in the number of endothelial cells in non-necrotic areas and a decrease in vascular permeability.
  • In Vitro
    KRN-633 inhibits tyrosine phosphorylation of VEGFR-1, VEGFR2, c-Kit, and PDGFR-β (IC50=11.7, 1.16, 8.01, 130 nM) in human umbilical vein endothelial cells. KRN-633 also inhibits the VEGF-driven proliferation of HUVECs (IC50=14.9 nM). KRN-633 suppresses capillary tube formation of endothelial cells.
  • In Vivo
    KRN-633 inhibits tumor growth in several tumor xenograft models with diverse tissue origins, including lung, colon, and prostate, in athymic mice and rats. KRN-633 also causes the regression of some well-established tumors and those that have regrown after the cessation of treatment. KRN-633 is well tolerated and has no significant effects on body weight or the general health of the animals. Histologic analysis of tumor xenografts treated with KRN-633 reveals a reduction in the number of endothelial cells in non-necrotic areas and a decrease in vascular permeability.
  • Synonyms
    KRN633 | KRN-633 | KRN 633
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    VEGFR1|VEGFR2|VEGFR3
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    286370-15-8
  • Formula Weight
    416.86
  • Molecular Formula
    C20H21ClN4O4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 8 mg/mL; 19.19 mM
  • SMILES
    CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl
  • Chemical Name
    1-(2-chloro-4-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-propylurea

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Nakamura K, et al. KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. Mol Cancer Ther. 2004 Dec;3(12):1639-49.
molnova catalog
related products
  • Didymin

    Didymin has antioxidant property. Didymin induces apoptosis by inhibiting N-Myc and upregulating RKIP in neuroblastoma, may used for neuroblastoma therapy.

  • Luteolin-3-O-beta-D-...

    Luteolin-3-O-beta-D-glucuronide is active in the inhibition of nitrite production in macrophages.

  • 3-Chloro-L-Tyrosine

    3-Chlorotyrosine a specific marker of myeloperoxidase-catalyzed oxidation is markedly elevated in low-density lipoprotein isolated from human atherosclerotic intima. In particular myeloperoxidase halogenates tyrosine residues in plasma proteins and generates 3-chlorotyrosine (CY).